Levact

Bendamustine Hydrochloride, the active ingredient in Levact, is an alkylating agent presented as an injectable solution for intravenous use. It forms DNA cross‑links that inhibit synthesis and induce apoptosis in malignant cells, and it is used to treat chronic lymphocytic leukemia and non‑Hodgkin lymphoma in adult patients.

GNH USA supplies Levact as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, providing reliable access to this EU‑approved chemotherapy agent.

Levact (bendamustine hydrochloride) is indicated for hematologic malignancies that respond to alkylating chemotherapy.

- Chronic lymphocytic leukemia: improves remission rates and prolongs progression‑free survival. - Non‑Hodgkin lymphoma: induces tumor regression and extends overall survival. - Indolent B‑cell lymphoma: provides disease control in patients unsuitable for more intensive regimens.

Bendamustine hydrochloride may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea and vomiting - Fatigue or weakness - Neutropenia (low neutrophil count) - Thrombocytopenia (low platelet count)

Serious or Rare Side Effects: - Severe infections, including sepsis - Pulmonary toxicity such as interstitial pneumonitis - Secondary malignancies, e.g., therapy‑related myelodysplastic syndrome - Anaphylactic or severe hypersensitivity reactions

When using Levact, clinicians should observe several safety measures to minimize risk.

- Monitor blood counts: perform regular CBC to detect neutropenia, anemia, or thrombocytopenia. - Assess organ function: evaluate hepatic and renal parameters before and during therapy. - Screen for infections: treat active infections prior to initiation and monitor for febrile episodes. - Use contraception: advise both male and female patients to use effective contraception during treatment and for several weeks after. - Avoid in hypersensitivity: discontinue if signs of severe allergic reaction appear. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Bendamustine hydrochloride can interact with other medicines, affecting its safety or efficacy.

Major Interactions (Avoid): - Concurrent use with other alkylating agents: may increase myelosuppression. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can raise bendamustine plasma levels. - Live vaccines: risk of infection due to immunosuppression. - High‑dose radiation therapy: heightened risk of tissue toxicity.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce drug exposure. - Anticoagulants (e.g., warfarin): monitor coagulation parameters for bleeding risk. - Supportive growth factors (e.g., G‑CSF): adjust dosing based on blood count response. - Diuretics: observe electrolyte balance and renal function.